Entecavir
- Generic Name
- Entecavir
- Brand Names
- Baraclude, Entecavir Viatris (previously Entecavir Mylan), Entecavir Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C12H15N5O3
- CAS Number
- 142217-69-4
- Unique Ingredient Identifier
- NNU2O4609D
- Background
Entecavir is an oral antiviral drug used in the treatment of hepatitis B infection. It is marketed under the trade name Baraclude (BMS).
...
- Indication
For the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.
- Associated Conditions
- Chronic Hepatitis B Infection
- Associated Therapies
- -
Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2019-03-25
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 4
- Registration Number
- NCT03887702
- Locations
- 🇺🇸
Prisma Health Cancer Institute - Easley, Easley, South Carolina, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸Health Partners Inc, Minneapolis, Minnesota, United States
The Efficacy and Safety of Nucleos(t)Ide Analogues in the Treatment of HBV-related Acute-on-chronic Liver Failure
- Conditions
- Interventions
- First Posted Date
- 2018-08-21
- Last Posted Date
- 2023-02-09
- Target Recruit Count
- 200
- Registration Number
- NCT03640728
- Locations
- 🇨🇳
The Affiliated Hospital of Yan'an University, Yan'an, China
🇨🇳Hanzhong Infectious Hospital, Hanzhong, China
🇨🇳Weinan Central Hospital, Weinan, China
The Curative Effect of Entecavir Combined Resveratrol on HBV patients-a Multi-center, Random, Open Clinical Trial
- Conditions
- Interventions
- First Posted Date
- 2018-04-26
- Last Posted Date
- 2018-04-26
- Lead Sponsor
- The First Hospital of Jilin University
- Target Recruit Count
- 312
- Registration Number
- NCT03509688
Efficacy and Safety of Combination Therapy of Thymalfasin and Entecavir in HBeAg-positive ETV-experienced Patients
- First Posted Date
- 2018-02-28
- Last Posted Date
- 2018-02-28
- Lead Sponsor
- Wen-hong Zhang
- Target Recruit Count
- 240
- Registration Number
- NCT03448744
- Locations
- 🇨🇳
Huashan Hospital of Fudan University, Shanghai, Shanghai, China
A Real-World Study of Pegylated Interferon In Nucleoside-treated Patients With Chronic Hepatitis B
- Conditions
- Interventions
- First Posted Date
- 2017-11-30
- Last Posted Date
- 2018-04-25
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 2000
- Registration Number
- NCT03357822
- Locations
- 🇨🇳
BeiJing YouAn Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳The First Hospital Affiliated to AMU, Chongqing, Chongqing, China
🇨🇳The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
Magnesium Isoglycyrrhizinate Followed by Diammonium Glycyrrhizinate and Combined With Entecavir in Chronic Hepatitis B
- First Posted Date
- 2017-11-21
- Last Posted Date
- 2017-11-21
- Lead Sponsor
- Cttq
- Target Recruit Count
- 480
- Registration Number
- NCT03349008
Entecavir for Decompensated HBV Cirrhosis
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2019-09-24
- Target Recruit Count
- 32
- Registration Number
- NCT03345498
- Locations
- 🇮🇳
Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, UP, India
Sequential/Combination Therapy in Nucleoside or Nucleotide Analogue (NA)-Suppressed Chronic Hepatitis B Patients
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2017-11-06
- Lead Sponsor
- Qin Ning
- Target Recruit Count
- 15
- Registration Number
- NCT03332329
Evaluation of the Safety and Pharmacology of EYP001 in HBV Subjects
- Conditions
- Interventions
- First Posted Date
- 2017-09-05
- Last Posted Date
- 2018-08-21
- Lead Sponsor
- Enyo Pharma
- Target Recruit Count
- 73
- Registration Number
- NCT03272009
- Locations
- 🇦🇺
Scientia Clinical Research Limited, Sydney, New South Wales, Australia
🇳🇱Academic Medical Centre (AMC), Amsterdam, Netherlands
🇳🇱Erasmus MC, Rotterdam, Netherlands
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Entecavir Extended Release (XR) in Healthy Subjects
- First Posted Date
- 2017-08-04
- Last Posted Date
- 2018-06-27
- Lead Sponsor
- Aucta Pharmaceuticals, Inc
- Target Recruit Count
- 40
- Registration Number
- NCT03239353
- Locations
- 🇦🇺
Linear Clinical Research Ltd, Nedlands, Western Australia, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.